Veracyte Inc (VCYT)
Veracyte, Inc. is a healthcare company focused on molecular diagnostics, with operations in the United States and international markets. The company develops and markets tests used in cancer diagnosis, including Afirma for thyroid nodules, Decipher assays for prostate and bladder cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also provides nCounter analysis system services. Incorporated in 2006 and headquartered in South San Francisco, California, the company was previously known as Calderome, Inc. before adopting its current name in March 2008. Veracyte’s common stock is listed on the NASDAQ exchange under the symbol VCYT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VCYT
|
$48.57
|
-18.3% Downside
|
Overvalued
|
$56.55
|
-4.9% Downside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
53.5x
|
3.5x
|
8.7x
|
4.569 B
|
4.306 B
|
0.9%
|
99.4%
|
31.3
|
—
|
176.5%
|
